Inclusion Criteria:  Informed consent obtained before any programme-related activities. Programme-related activities are any procedures that are carried out as part of the programme.  Patients with congenital haemophilia:  severe haemophilia A (coagulation factor VIII (FVIII) less than 1%) or moderate/severe haemophilia B (coagulation factor IX (FIX) less than or equal to 2%) without inhibitors or any haemophilia severity with documented history of inhibitors (more than or equal to 0.6 bethesda unit (BU)) who cannot be treated satisfactorily with authorised and marketed medicines (example: due to inhibitors or allergic reactions to factor-containing products, or due to poor venous access), and who are not able to enrol in clinical trials designed to support the development and registration of concizumab medicines (example: due to inhibitors or allergic reactions to factor-containing products, or due to poor venous access) as per investigator and Novo Nordisk assessment. The potential benefit for the individual patient justifies the potential risks of treatment.  Exclusion Criteria:  Known or suspected hypersensitivity to investigational medicinal product or related products. Any condition (current or medical history), which in the investigator's or Novo Nordisk's opinion might jeopardise patient's safety or compliance with the protocol.